Article

Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in Adults

2022-10-19

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> This interim analysis of an ongoing phase I randomized clinical trial evaluated the safety, reactogenicity, and immunogenicity of mRNA-1283, a next-generation SARS-CoV-2 messenger RNA (mRNA)-based vaccine encoding 2 segments of the spike protein (ie, receptor binding and N-terminal domains). <h4>Methods</h4> Healthy aged adults 18-55 years (n = 104) were randomized (1:1:1:1:1)...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2777f9f7-0523-50cb-be79-95259e0b64fc
DOI: 10.1101/2022.10.18.22281050

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in AdultsDOI 10.1101/2022.10.18.22281050Read

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim AnalysisSemantic proximity Read

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA VaccineSemantic proximity Read

Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent VaccinesSemantic proximity Read

Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)Semantic proximity Read

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsSemantic proximity Read

Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domainsSemantic proximity Read

Immunogenicity and Reactogenicity of Heterologous and Homologous mRNA-1273 and BNT162b2 Vaccination: A Multicenter Non-Inferiority Randomized TrialSemantic proximity Read

Serum Neutralizing Activity of mRNA-1273 Against the SARS-CoV-2 B.1.1.529 (Omicron) Variant: A Preliminary ReportSemantic proximity Read

Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-BSemantic proximity Read

Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2Semantic proximity Read

Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.SSemantic proximity Read

Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine BoosterSemantic proximity Read